ReviewEndocrinology and metabolism clinics of North America2017
Biochemical Testing in Neuroendocrine Tumors.
Review in Endocrinology and metabolism clinics of North America, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 53 citations in OpenAlex.
- The specificity trap in routine tumor biomarker interpretation: Advancing the 3PM-based clinical decision framework to benefits of patients.The EPMA journal · 2026Review
- From pulmonary embolism to small intestinal neuroendocrine tumor: A new diagnostic perspective.The Journal of international medical research · 2026Article
- Bilateral carcinoid heart disease secondary to a massive right-to-left shunt through a patent foramen ovale: a case report.European heart journal. Case reports · 2025Article
- Serum Concentrations of Selected Biological Factors as a Potential Tool for Detecting Recurrence in Endocrine Tumors-A Pilot Study.Journal of clinical medicine · 2025Article
- Dynamic nomogram for predicting the overall survival and cancer-specific survival of patients with gastrointestinal neuroendocrine tumor: a SEER-based retrospective cohort study and external validation.Frontiers in oncology · 2025Article
- The Role of Small-Bowel Endoscopy in the Diagnosis and Management of Small-Bowel Neuroendocrine Tumours.Journal of clinical medicine · 2024Review
- Article
- Non-specific Symptoms of Small Bowel Neuroendocrine Tumor and the Diagnostic Challenges: A Case Report.Cureus · 2023Article
- Article
- An unusual presentation of accessory spleen mimicking a pancreatic neoplastic lesion in a splenectomized patient: A case report.SAGE open medical case reports · 2023Article
- Case Report: Carcinoid heart disease with severe tricuspid regurgitation and concomitant patent foramen ovale causing severe hypoxia.Frontiers in cardiovascular medicine · 2023Article
- Circulating Neuroendocrine Tumor Biomarkers: Past, Present and Future.Journal of clinical medicine · 2022Review
- Diagnosis and management of small bowel neuroendocrine tumors: A state-of-the-art.World journal of methodology · 2022Review
- Pro-Gastrin-Releasing Peptide as a Marker of Small Cell Lung Cancer.Bulletin of experimental biology and medicine · 2022Article
- Neuroendocrine Tumor with Metachronous Gastrointestinal Stromal Tumor in a Patient: A Case Report.The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi · 2022Article
- Use of healthcare REsources and associated COsts in controlled versus uncontrolled carcinoid SYndrome in patients with neuroendocrine tumours: the RECOSY study.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2021Observational
- Can an amino acid mixture alleviate gastrointestinal symptoms in neuroendocrine tumor patients?BMC cancer · 2021Article
- Diagnosis and Management of Gastrointestinal Neuroendocrine Tumors: A Comprehensive Literature Review.Cureus · 2021Review
- Serotonin pathway in carcinoid syndrome: Clinical, diagnostic, prognostic and therapeutic implications.Reviews in endocrine & metabolic disorders · 2020Review
- Right and Left-Sided Carcinoid Heart Disease in the Setting of Selective Serotonin Reuptake Inhibitor Use.JACC. Case reports · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Neuroendocrine cells are widely distributed throughout the body. They can produce, store, and secrete peptides and biogenic amines. Neuroendocrine tumors (NETs) are rare, but most are found in the intestine, pancreas, and lung. NETs may cause specific hormonal symptoms (eg, carcinoid syndrome) or appear nonfunctional. Blood or urine concentrations of tumor-secreted amines and peptides have been used as biomarkers in the diagnosis and management of NETs. This article focuses on currently available biochemical testing of blood or urine for gastroenteropancreatic and lung NETs and discusses the limitations of these tests and the potential role of newer multianalyte markers for NET management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.